Latest News and Press Releases

Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer

Immuneering Announces Positive Initial Phase 2a Data Including Complete and Partial Responses with IMM-1-104 in Combination with Chemotherapy in First-Line

Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates

Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer

Immuneering to Present at the Jefferies Global Healthcare Conference

Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates

Immuneering Recognizes Melanoma Awareness Month

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models

Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations